Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Astellas Gears Up to Accelerate R&D
July 24, 2014
- Maruho Seeks Approval of Antibacterial Drug Ozenoxacin in Japan
July 24, 2014
- Japan Antidepressant Market Valued at 151 Billion Yen in 2022
July 24, 2014
- Jiangsu Hengrui Medicine of China Establishes Japanese Subsidiary; Aims for Sales of 10 Billion Yen by 2022
July 24, 2014
- Takeda, ASKA to Cease Seltouch Marketing by Late September
July 24, 2014
- Kyorin Licenses OAB Treatment Vibegron from Merck
July 24, 2014
- Research Lab for High-Value Generics Goes Live: Kobayashi Kako
July 23, 2014
- Terumo US Unit Opens New Plant in Vietnam
July 23, 2014
- Tatsumi Kagaku Adjusts Supply of Nu-lotan Generic
July 22, 2014
- Disclosure of Payments from Drug Makers to Doctors Delayed
July 22, 2014
- Chugai Obtains Marketing Rights for Antiemetic NEPA in the UK, Ireland from Helsinn Group
July 22, 2014
- Ethical Drug Sales Down 6.5% in May: Crecon Report
July 18, 2014
- Novartis, Maruho Form Sales Tie-Up for Psoriasis Agent
July 18, 2014
- Carna Shooting for 1st Licensing Deal on Kinase Inhibitor in 2014
July 18, 2014
- Ono to Target Cancers with Unmet Medical Needs: President
July 18, 2014
- AnGes MG Initiates Development of Next Generation Collategene
July 18, 2014
- OncoTherapy Appoints Prof. Nakamura as Special Science Advisor
July 18, 2014
- Merck Serono Japan Hopes to Boost Erbitux Share by Narrowing Down CRC Patients: President
July 17, 2014
- Chugai, Zeltia Sign Commercialization Agreement for Plitidepsin in Europe
July 17, 2014
- AZ Begins Nexium Clinical Study for Pediatric Use in Japan
July 17, 2014
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…